These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36301434)

  • 1. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
    Schneider R; Oh J
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
    Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations.
    Krämer J; Wiendl H
    Curr Opin Neurol; 2024 Jun; 37(3):237-244. PubMed ID: 38533819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis.
    Saberi D; Geladaris A; Dybowski S; Weber MS
    Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
    Geladaris A; Torke S; Weber MS
    CNS Drugs; 2022 Oct; 36(10):1019-1030. PubMed ID: 36178589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.
    Weber MS; Nicholas JA; Yeaman MR
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34497100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis.
    Turner TJ; Brun P; Gruber RC; Ofengeim D
    Drugs R D; 2024 Jun; 24(2):263-274. PubMed ID: 38965189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
    Carnero Contentti E; Correale J
    Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
    Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
    Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier.
    Greenberg BM
    Neurol Clin; 2024 Feb; 42(1):155-163. PubMed ID: 37980113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
    Torke S; Pretzsch R; Häusler D; Haselmayer P; Grenningloh R; Boschert U; Brück W; Weber MS
    Acta Neuropathol; 2020 Oct; 140(4):535-548. PubMed ID: 32761407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the Role of the Glycogen Synthase Kinase-3β, Bruton's Tyrosine Kinase, and Sphingosine 1 Phosphate Pathways in Multiple Sclerosis.
    Mohite R; Gharat S; Doshi G
    Endocr Metab Immune Disord Drug Targets; 2024; 24(10):1131-1145. PubMed ID: 38284723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.
    Himmelbauer MK; Bajrami B; Basile R; Capacci A; Chen T; Choi CK; Gilfillan R; Gonzalez-Lopez de Turiso F; Gu C; Hoemberger M; Johnson DS; Jones JH; Kadakia E; Kirkland M; Lin EY; Liu Y; Ma B; Magee T; Mantena S; Marx IE; Metrick CM; Mingueneau M; Murugan P; Muste CA; Nadella P; Nevalainen M; Parker Harp CR; Pattaropong V; Pietrasiewicz A; Prince RJ; Purgett TJ; Santoro JC; Schulz J; Sciabola S; Tang H; Vandeveer HG; Wang T; Yousaf Z; Helal CJ; Hopkins BT
    J Med Chem; 2024 May; 67(10):8122-8140. PubMed ID: 38712838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.
    Geladaris A; Torke S; Saberi D; Alankus YB; Streit F; Zechel S; Stadelmann-Nessler C; Fischer A; Boschert U; Häusler D; Weber MS
    Acta Neuropathol; 2024 Apr; 147(1):75. PubMed ID: 38656399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the treatment of primary and secondary progressive Multiple Sclerosis.
    Sriwastava S; Elkhooly M; Amatya S; Shrestha K; Kagzi Y; Bhatia D; Gupta R; Jaiswal S; Lisak RP
    J Neuroimmunol; 2024 May; 390():578315. PubMed ID: 38554666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton tyrosine kinase inhibitors for multiple sclerosis.
    Krämer J; Bar-Or A; Turner TJ; Wiendl H
    Nat Rev Neurol; 2023 May; 19(5):289-304. PubMed ID: 37055617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's tyrosine kinase inhibition for the treatment of allergic disorders.
    Lin EV; Suresh RV; Dispenza MC
    Ann Allergy Asthma Immunol; 2024 Jul; 133(1):33-42. PubMed ID: 38492772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X; Arnold DL; Weber MS; Staikov I; Piasecka-Stryczynska K; Willmer J; Martin EC; Dangond F; Syed S; Wolinsky JS;
    N Engl J Med; 2019 Jun; 380(25):2406-2417. PubMed ID: 31075187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Hatashima A; Karami M; Shadman M
    Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.